SMITHS FALLS, ON & INCLINE VILLAGE, NV – Canopy Growth Corporation (TSX:WEED) (“Canopy Growth” or “the Company”) and Farm to Farma Inc. (“FTF”) today announced that they have signed a definitive licensing agreement for FTF’s innovative Trokie® lozenges. Under this licensing agreement, Canopy Growth will have the exclusive right to manufacture and distribute FTF’s Trokie® lozenges through its subsidiaries in Canada, as permitted by federal regulations, and shall have a first right of offer for all other countries, excluding the United States.
Developed by a Doctor of Pharmacy, Trokie® lozenges have been developed to deliver a consistent and repeatable dose of cannabis to its users. Trokie® features the most used polymer-based drug delivery system which allows for a zero-calorie product that avoids most common food allergies. There is no gluten, nuts, artificial flavours or colours, and the product meets vegan standards, utilizing many organic/natural ingredients. Trokie® products are currently available for sale through dispensaries in Nevada, California, Oregon, and Arizona.
“We are very pleased to have entered into this license agreement for the Trokie® lozenges, a cannabis product that we believe has broad medical and recreational market opportunities,” said Mark Zekulin, President, Canopy Growth Corporation. “We are confident value-added consumer products will drive higher margins and we will continue to look for thought leaders like Farm to Farma to expand our product offerings.”
Current ACMPR regulations allow for oil-based and dried cannabis products only, but Canopy Growth continues its licensing, and research and development programs to position itself for rapid diversification if and when the regulations allow for more varied formats in medical and recreational markets.
“Signing this agreement with Canopy Growth is an exciting development for our company,” said Shane Johnson, President, Farm to Farma Inc. “Combining Canopy’s vision for the future of cannabis in consumer products and the deliberate investments they are making in capacity, with our unique line of products, has positioned us to increase our global footprint with the largest and most-respected cannabis company in the world.”
The Farm to Farma’s Trokie® lozenge was designed specifically with the patient in mind. It is covered by an issued patent in the U.S., and is patent-pending in other jurisdictions including Canada. “By utilizing the oral mucosa for delivery, these lozenges have been developed to minimize first past metabolism of cannabinoids by the liver, deliver a rapid onset of action, and optimize the bioavailability of every dose,” said Dr. Kenton Crowley, the inventor of the Trokie®lozenge. Additional products such as transdermal patches and capsules are being added to the suite of products available under the Trokie® brand.
Here’s to Future Growth.
Director of Communications
855-558-9333 ex 122